Filing Flows › bioAffinity Technologies (BIAF) › R&D spending
bioAffinity Technologies (BIAF) R&D spending by quarter
bioAffinity Technologies' R&D spending was $389K in Q3 2026 (third quarter 2026), +8% from Q2 2026. Over the last 7 quarters it ranged from $311K (Q2 2025) to $389K (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $389K | +8% | +18% |
| Q2 2026 | $362K | +3% | +16% |
| Q1 2026 | $350K | -6% | -5% |
| Q4 2025 | $374K | +13% | — |
| Q3 2025 | $331K | +6% | — |
| Q2 2025 | $311K | -15% | — |
| Q1 2025 | $367K | — | — |
Q3 2026 at a glance
bioAffinity Technologies, Q3 2026: revenue $1.1M (-26% year over year), operating margin -328.0%, net loss $5.3M, operating cash flow −$3.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is bioAffinity Technologies' R&D spending?
bioAffinity Technologies' R&D spending was $389K in Q3 2026 (third quarter 2026), +8% from Q2 2026.
How has bioAffinity Technologies' R&D spending changed?
Over the last 7 quarters it ranged from $311K (Q2 2025) to $389K (Q3 2026).
Q3 2026 results → · How bioAffinity Technologies makes money →